Truist analyst Richard Newitter raised the firm’s price target on Integra LifeSciences to $62 from $58 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 earnings in MedTech space. The intra-quarter feedback, including the firm’s Q1 hospital utilization survey leaves Truist bullish on underlying Q1 utilization trends for the sector and confident that MedTech companies will likely deliver in-line or better top-line results with modestly raised organic 2023 revenue outlooks, though the sector’s rally and raised expectations in recent weeks is also already likely reflected to some degree in valuations, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IART:
- Integra LifeSciences to Host First Quarter 2023 Financial Results Conference Call on April 26, 2023
- Integra LifeSciences sees Q1 adjusted EPS 72c-76c, consensus 79c
- Integra LifeSciences sees FY23 adjusted EPS $3.43-$3.51, consensus $3.52
- Integra LifeSciences reports Q4 adjusted EPS 94c, consensus 90c
- Integra LifeSciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance